CINGULATE INC. news, videos and press releases - Page 2
For more news please use our advanced search feature.
CINGULATE INC. - More news...
CINGULATE INC. - More news...
- Cingulate Announces Pricing of $7.5 Million Public Offering
- Longtime Cingulate Controller Jennifer Callahan Promoted to CFO
- Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market
- Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)
- Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update
- Cingulate to Host CNS Key Opinion Leader Panel in New York City
- Cingulate Inc. to Present at the LD Micro Main Event XVI
- Cingulate Announces Closing of $4.0 Million Public Offering
- Cingulate Announces Pricing of $4.0 Million Public Offering
- Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD
- Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium
- Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023
- Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update
- Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD
- Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August
- Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-Vest
- Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD
- Cingulate to Present at 13th Annual LD Micro Invitational
- Cingulate, Indegene to Participate in Benzinga All Live Access Event
- Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update
- Cingulate Announces Successful Transfer of CTx-1301 (dexmethylphenidate) Proprietary PTR™ Manufacturing Processes to Societal CDMO
- Cingulate to Participate in Benzinga All Live Access Event
- Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHD
- Cingulate and Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301
- Cingulate Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update
- Cingulate Announces Positive Top-Line Results from Fed/Fast Study of Lead Asset CTx-1301 for ADHD
- Cingulate Initiates Phase 3 Study of Lead Asset CTx-1301, Designed as a True Entire Active-Day Treatment for ADHD
- Cingulate Benzinga All Live Access Appearance Rescheduled for December 16
- Cingulate to Participate in Benzinga All Live Access Event
- Cingulate Inc. Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update
